The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here:

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Thoas Fioretos

Thoas Fioretos

Research team manager

Thoas Fioretos

PAX5 is part of a functional transcription factor network targeted in lymphoid leukemia


  • Kazuki Okuyama
  • Tobias Strid
  • Jacob Kuruvilla
  • Rajesh Somasundaram
  • Susana Cristobal
  • Emma Smith
  • Mahadesh Prasad
  • Thoas Fioretos
  • Henrik Lilljebjörn
  • Shamit Soneji
  • Stefan Lang
  • Jonas Ungerbäck
  • Mikael Sigvardsson

Summary, in English

One of the most frequently mutated proteins in human B-lineage leukemia is the transcription factor PAX5. These mutations often result in partial rather than complete loss of function of the transcription factor. While the functional dose of PAX5 has a clear connection to human malignancy, there is limited evidence for that heterozygote loss of PAX5 have a dramatic effect on the development and function of B-cell progenitors. One possible explanation comes from the finding that PAX5 mutated B-ALL often display complex karyotypes and additional mutations. Thus, PAX5 might be one component of a larger transcription factor network targeted in B-ALL. To investigate the functional network associated with PAX5 we used BioID technology to isolate proteins associated with this transcription factor in the living cell. This identified 239 proteins out of which several could be found mutated in human B-ALL. Most prominently we identified the commonly mutated IKZF1 and RUNX1, involved in the formation of ETV6-AML1 fusion protein, among the interaction partners. ChIP- as well as PLAC-seq analysis supported the idea that these factors share a multitude of target genes in human B-ALL cells. Gene expression analysis of mouse models and primary human leukemia suggested that reduced function of PAX5 increased the ability of an oncogenic form of IKZF1 or ETV6-AML to modulate gene expression. Our data reveals that PAX5 belong to a regulatory network frequently targeted by multiple mutations in B-ALL shedding light on the molecular interplay in leukemia cells.


  • Molecular Lymphopoiesis
  • StemTherapy: National Initiative on Stem Cells for Regenerative Therapy
  • Division of Molecular Hematology (DMH)
  • BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation
  • Translational Genomic and Functional Studies of Leukemia
  • Division of Clinical Genetics

Publishing year





PLoS Genetics





Document type

Journal article


Public Library of Science (PLoS)


  • Medical Genetics



Research group

  • Molecular Lymphopoiesis
  • Translational Genomic and Functional Studies of Leukemia


  • ISSN: 1553-7404